Upcoming Conferences for Relay Therapeutics
Relay Therapeutics, Inc. (Nasdaq: RLAY), a pioneering precision medicine company, has exciting news regarding their upcoming participation in two important investor conferences. These events represent a significant opportunity for Relay Therapeutics to engage with investors and highlight their innovative approach to drug discovery.
Participation Details
The company will be part of the TD Cowen’s 45th Annual Health Care Conference, which takes place shortly. This event is scheduled for a time slot at 1:50 p.m. ET, where key management will share insights into the company's ongoing projects and future direction.
Barclays Healthcare Conference Slot
Additionally, Relay Therapeutics will also attend the Barclays 27th Annual Global Healthcare Conference on a different date, set for Tuesday at 11:00 a.m. ET. This dual participation underscores the company's commitment to fostering relationships with investors and stakeholders alike.
Webcast Availability
For those unable to attend, these fireside chats will be webcast live, presenting a convenient way for all interested parties to follow along. Interested attendees can find the live stream and further details on Relay Therapeutics’ official website in the Events section. Archive access will also be available for viewers who prefer to catch up afterward, with replays lasting up to 30 days post-event.
About Relay Therapeutics
Relay Therapeutics stands at the forefront of precision medicine, revolutionizing the landscape of drug discovery. By leveraging advanced computational and experimental methodologies, they aim to develop therapies that truly change lives.
The Dynamo® Platform
A key component of their transformative efforts is the Dynamo® platform that integrates a variety of innovative techniques. This platform is designed to tackle complex protein targets that have either been challenging to address or overlooked in traditional drug development pathways.
Focused Areas of Development
Currently, Relay Therapeutics concentrates on enhancing small molecule therapeutic discoveries for targeted oncology and genetic disease treatments. Their focus on these areas not only showcases their operational strategy but also aligns their goals with pressing healthcare needs, aimed at delivering actionable results and effective solutions for patients.
Contact Information
For further inquiries, individuals can reach out to Pete Rahmer for corporate communications. He is accessible via email, ensuring that all stakeholders can easily connect with Relay Therapeutics for any questions or discussions related to the company’s engagements.
Frequently Asked Questions
What is Relay Therapeutics focusing on at the conferences?
The company aims to engage investors and showcase their innovative approach to drug discovery.
How can I access the conference webcasts?
Webcasts will be available live on Relay Therapeutics’ website, with archived versions accessible for 30 days after each event.
What technology does Relay Therapeutics use for drug discovery?
Relay Therapeutics utilizes their advanced Dynamo® platform, which combines computational and experimental techniques.
What areas are they targeting for therapy development?
The company is currently focused on small molecule therapeutics aimed at oncology and genetic diseases.
Who can I contact for more information about Relay Therapeutics?
For inquiries, please contact Pete Rahmer directly at his email address available on their website.
